These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 9893768

  • 1. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
    Cazzola M, Vinciguerra A, Di Perna F, Matera MG.
    Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
    [Abstract] [Full Text] [Related]

  • 2. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
    Cazzola M, Di Perna F, Noschese P, Vinciguerra A, Calderaro F, Girbino G, Matera MG.
    Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ, Winter TH, Aalbers R.
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
    Ulrik CS.
    Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
    [Abstract] [Full Text] [Related]

  • 7. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease.
    Matera MG, Cazzola M, Vinciguerra A, Di Perna F, Calderaro F, Caputi M, Rossi F.
    Pulm Pharmacol; 1995 Dec; 8(6):267-71. PubMed ID: 8819181
    [Abstract] [Full Text] [Related]

  • 8. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
    Cazzola M, Santangelo G, Piccolo A, Salzillo A, Matera MG, D'Amato G, Rossi F.
    Pulm Pharmacol; 1994 Apr; 7(2):103-7. PubMed ID: 7915921
    [Abstract] [Full Text] [Related]

  • 9. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G.
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [Abstract] [Full Text] [Related]

  • 10. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
    Jarvis B, Markham A.
    Drugs Aging; 2001 May; 18(6):441-72. PubMed ID: 11419918
    [Abstract] [Full Text] [Related]

  • 11. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.
    Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP.
    Thorax; 1996 Jul; 51(7):689-93. PubMed ID: 8882074
    [Abstract] [Full Text] [Related]

  • 12. [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].
    Ulrik CS.
    Ugeskr Laeger; 1996 Jun 17; 158(25):3604-7. PubMed ID: 8693619
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
    van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM.
    Eur Respir J; 2000 May 17; 15(5):878-85. PubMed ID: 10853852
    [Abstract] [Full Text] [Related]

  • 14. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
    Higham MA, Sharara AM, Wilson P, Jenkins RJ, Glendenning GA, Ind PW.
    Thorax; 1997 Nov 17; 52(11):975-80. PubMed ID: 9487346
    [Abstract] [Full Text] [Related]

  • 15. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.
    Cazzola M, Calderaro F, Califano C, Di Pema F, Vinciguerra A, Donner CF, Matera MG.
    Eur J Clin Pharmacol; 1999 Jan 17; 54(11):829-33. PubMed ID: 10027655
    [Abstract] [Full Text] [Related]

  • 16. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
    Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, Murphy D, Kram JA, Hardie G, Reuter C, Ostransky D, McFarland K, Petty TL, Silvers W, Rennard SI, Mueller M, Repsher LH, Zuwallack RL, Vale R.
    Am J Med; 1996 Jan 29; 100(1A):40S-48S. PubMed ID: 8610716
    [Abstract] [Full Text] [Related]

  • 17. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
    Taccola M, Bancalari L, Ghignoni G, Paggiaro PL.
    Monaldi Arch Chest Dis; 1999 Aug 29; 54(4):302-6. PubMed ID: 10546469
    [Abstract] [Full Text] [Related]

  • 18. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study.
    Boulet LP, Laviolette M, Boucher S, Knight A, Hébert J, Chapman KR.
    J Allergy Clin Immunol; 1997 Jan 29; 99(1 Pt 1):13-21. PubMed ID: 9003206
    [Abstract] [Full Text] [Related]

  • 19. Rapid onset of tolerance to the bronchoprotective effect of salmeterol.
    Bhagat R, Kalra S, Swystun VA, Cockcroft DW.
    Chest; 1995 Nov 29; 108(5):1235-9. PubMed ID: 7587422
    [Abstract] [Full Text] [Related]

  • 20. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease.
    Cazzola M, Matera MG, Di Perna F, Calderaro F, Califano C, Vinciguerra A.
    Respir Med; 1998 Feb 29; 92(2):354-7. PubMed ID: 9616538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.